Search Results for 'dronedarone'

April 6th, 2010

• Dronedarone Data Duel

Dronedarone Data Duel: Two separate papers in the Journal of the American College of Cardiology offer starkly contrasting views on the role of dronedarone in clinical practice. In a viewpoint and commentary, David Singh and colleagues review the dronedarone data and conclude that although dronedarone “has the ability to control both rhythm and rate” in AF patients, […]


March 30th, 2010

• FDA Issues Complete Response Letter For Certriad
• U.K.’s NICE Goes Easier on Dronedarone
• U.S. Justice Dep’t & SEC Look Into Boston Scientific ICD Recall

FDA Issues Complete Response Letter For Certriad: The FDA issued a complete response letter for the NDA for Certriad, Abbot’s and AstraZeneca’s combination pill composed of rosuvastatin and fenofibric acid delayed release. The companies did not release any details of the letter, but analysts think it will mean the drug’s approval will likely be delayed […]


January 26th, 2012

Sizing Up Clinical Trials — Quickly and Intuitively

A pharmaceutical sales rep comes to your office bringing lunch. He shows you a graphic stating that Multaq (dronedarone) reduced the primary endpoint in the ATHENA trial by 24%. The fine print shows an impressive P value: <0.0001. You come away satisfied that this drug looks good. You may not realize it, but you also […]


January 3rd, 2012

A Look Forward to 2012

CardioExchange invited contributors and members to offer predictions for 2012. Several of these folks also offered predictions for last year and helped assess the most important developments in cardiology in 2011. What are your predictions for the year? Where have our Nostradamus’ gone wrong? Steven E Nissen, MD 1. In a 5:4 vote, the U.S. […]


November 18th, 2011

AHA.11 Roundup

Whether you were in Orlando for AHA.11 or not, you’ll want to check out our coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting. VIEWS AND ANALYSIS ROUNDTABLE: After SATURN, What Role for Rosuvastatin? A CardioExchange Panel: Steven Nissen, […]


November 10th, 2011

The AHA in Orlando: A Preview

The AHA 2011 Scientific Sessions start this weekend in Orlando. CardioExchange received a preview of some of the many expected highlights of the meeting from Program Chair Elliott Antman. (Click here to view AHA videos of Antman’s meeting previews.) Antman stressed the sheer size and magnitude of the meeting: 742 individual sessions, 4238 abstracts selected out of […]


July 7th, 2011

Multaq’s Off Again, On Again, Then Off Again Ride

CardioExchange welcomes this guest post, reprinted with permission, from Dr. Westby Fisher, an electrophysiologist practicing at NorthShore University HealthSystem in Evanston, Illinois, and a Clinical Associate Professor of Medicine at University of Chicago’s Pritzker School of Medicine. This piece originally appeared on his blog, Dr. Wes. Today was another tough day for Sanofi’s dronedarone antiarrhythmic medication (marketed as Multaq®) after […]


May 4th, 2011

Study Estimates That Atrial Fibrillation Adds $26 Billion to Yearly U.S. Healthcare Costs

Atrial fibrillation may add $26 billion to the nation’s healthcare bill, according to a study published in Circulation: Cardiovascular Quality and Outcomes. Michael Kim and colleagues compared insurance claims for 1 year from 89,066 AF patients with claims from controls matched for gender, age, and other medical conditions and found that AF results in a […]


February 14th, 2011

AF Guidelines Updated to Incorporate Dabigatran

Less than two months after the publication of the 2010 updated atrial fibrillation (AF) guidelines, the AHA, the ACC, and the HRS have released a new focused update incorporating recommendations and a discussion concerning the direct thrombin inhibitor dabigatran, which gains a Class I recommendation: Class I: Dabigatran is useful as an alternative to warfarin for […]


September 21st, 2010

See Everything

John Mandrola is a cardiac electrophysiologist and blogger on matters medical and general. Here is a recent post from his blog Dr John M. Do you see anything wrong with this picture? (Hint: see the right column) I guess the European electrophysiologists couldn’t wait for us in North America.  They have published their own 54,000 word Euro-specific guidance […]